Targeted corrective gene conversion (TCGC)
holds much promise as a future therapy for
many hereditary diseases in humans, but there
still remain significant impediments to
effective mutation correction and it is clear
that significant work remains to improve
TCGC to levels where it can be considered for
translation to the clinical setting.